Bye bye, Donald Kennedy

Yesterday (June 21), Science editor-in-chief Donald Kennedy announced he was retiring from the journal, after seven years at the helm. AAAS president David Baltimore is leading a search committee for a new candidate. Kennedy has steered Science through some tricky waters, to say the least. The journal published, then retracted, one of Woo-Suk Hwang's linkurl:now-infamous;http://www.the-scientist.com/news/display/36969/ papers on human embryonic stem cell research. In 2002, the journal lin

By | June 22, 2007

Yesterday (June 21), Science editor-in-chief Donald Kennedy announced he was retiring from the journal, after seven years at the helm. AAAS president David Baltimore is leading a search committee for a new candidate. Kennedy has steered Science through some tricky waters, to say the least. The journal published, then retracted, one of Woo-Suk Hwang's linkurl:now-infamous;http://www.the-scientist.com/news/display/36969/ papers on human embryonic stem cell research. In 2002, the journal linkurl:retracted;http://www.the-scientist.com/article/display/21593/ a controversial paper that suggested the recreational drug Ecstasy predisposed users to Parkinson disease, causing some researchers to demand to see the referees' reports. Kennedy also recently penned an "expression of concern" over a linkurl:paper;http://www.the-scientist.com/news/display/52847/ that showed two-cell embryos have distinct cell lineages. But Kennedy was no stranger to hoopla when he took the Science job, having resigned as president of Stanford University after the school became linkurl:enveloped in controversy;http://www.the-scientist.com/article/display/10955/ over indirect costs. During his tenure, Science has received an linkurl:increasing number;http://www.the-scientist.com/article/display/23061/ of submissions, "at a rate of growth rivaling the rate of Chinese economic growth," according to Kennedy. What do you think about Kennedy's tenure at Science? Tell us here.

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech